Journal Watch
Home HD Dose and Frequency Prescriptions
Current Kt/V formulas don’t guide nephrologists to prescribe home HD with low-flow machines. A study of 38 home HD patients resulted in 231 clinical data sets for urea modeling, which were analyzed using the Solute Solver software recommended by the KDOQI guidelines. The researchers chose 7 of the 62 potential combinations, assuming Monday blood draws, and found the new formula for stdKtV to be reliable and helpful for guiding clinicians.
Read the abstract » | (added 2023-10-13)
Tags: Home HD, Kt/V, Urea Modeling, StdKt/V
Melatonin Shows Promise for Preventing Peritoneal Fibrosis
Glucose in peritoneal dialysate drives inflammation and angiogenesis, which lead to fibrosis that can cause loss of use of the membrane. A new study from China proposes that melatonin may break this cycle.
Read the abstract » | (added 2023-10-13)
Tags: Melatonin, Peritoneal Fibrosis, Glucose, GSDME, Pyroptosis
Exercise and Quality of Life on PD
In a cross sectional study of 339 PD patients, 81.7% exercised a median of 5 hours per week, mainly slow walking. Those who exercised had better quality of life. Older age, female sex, higher BMI, and pain were independently associated with lower exercise capacity.
Read the abstract » | (added 2023-10-13)
Tags: PD, Exercise, Quality Of Life
Magnesium Inhibits the Peritoneal Calcification of Late-stage EPS in Mice
Encapsulating peritoneal sclerosis (EPS) is a devastating and potentially lethal complication of PD. The reasons for EPS are not clear, but phosphate loading seems to contribute to the condition. This study successfully induced peritoneal calcification in mice—and found that administering magnesium into the peritoneum suppressed fibrosis and calcification.
Read the abstract » | (added 2023-10-13)
Tags: Encapsulating Peritoneal Sclerosis, Magnesium, Peritoneal Calcification, EPS
Hypocrisy in Healthcare—Professional vs. Patient ESRD Modality Choices
An anonymous online UK survey of renal healthcare workers had 858 responses to two hypothetical questions about their own dialysis modality choice. While PD and home HD were strongly preferred, more than 80% of ESRD patients in the UK still receive standard in-center HD.
Read the abstract » | (added 2023-09-13)
Tags: Dialysis Modality, ESRD Modality
Intraperitoneal Pressure and Hernias
While it has long been believed that high intraperitoneal pressure (IPP) is a factor in hernia development, this notion had not been proven. A prospective observational study of 124 incident PD patients over a 10-year period suggests that the common wisdom was correct. Higher IPP at PD onset, older age, higher BMI, prior hernia, laparoscopic PD catheter placement, and technique failure were related to hernia formation.
Read the abstract » | (added 2023-09-13)
Tags: Intraperitoneal Pressure, IPP, Hernia, Incident PD, Hernia Formation Factors
Incremental PD and Patient Outcomes: Registry Data
Between 2007 and 2017, incremental PD use increased by 2.7% in the ANZDATA database. Most (67%) used the approach for one year or less. After controlling for patient and center variables, starting PD with incremental treatments reduced peritonitis risk and transfers to in-center HD, with no increase in mortality.
Read the abstract » | (added 2023-09-13)
Tags: Incremental PD, Incremental Treatments, Peritonitis, Mortality Rate
Incremental PD and Quality of Life
In a 4-year study (2015-2019) of adults starting PD and followed for one year, those who used incremental PD had better KDQOL physical composite, burden of kidney disease, and effects of kidney disease scores, as well as less hospitalization and lower mortality rates (non-significant).
Read the abstract » | (added 2023-09-13)
Tags: Incremental PD, KDQOL, Mortality Rate, Quality Of Life
Early Survival Advantage for Incremental PD
From 2008 to 2017, 1,315 patients from one hospital who started PD were enrolled in a study that propensity matched them 1 (incremental; n=285):2 (full dose; n=502) for age, sex, residual kidney function and urine volume, hemoglobin, serum albumin, and other variables. For the first 6 years, intermittent PD had significantly better survival than full dose PD, with a 39% lower risk of all-cause mortality and 41% less cardiovascular mortality. This advantage disappeared with longer time on PD.
Read the abstract » | (added 2023-09-13)
Tags: Intermittent PD, Full Dose PD, Mortality
Systemic Immune-Inflammation Index (SII) and Mortality on PD
Among 1,419 PD patients from 2007 to 2019, SII was calculated as platelet count x neutrophil count/lymphocyte count. During a median 42 month follow up, 321 patients died, 171 of cardiovascular disease. Each 1 standard deviation increase in the SII was associated with a 20.2% rise in all-cause mortality and 28% in cardiovascular-specific mortality.
Read the abstract » | (added 2023-09-13)